Brind.

Ironwood Pharmaceuticals receives 'hold' rating from Jefferies amid insider selling…

1 report, 1 independent Updated Sat 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Jefferies Financial Group upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report issued on Friday. This rating change occurred alongside disclosures of insider selling filed with the SEC. Ironwood Pharmaceuticals recently reported quarterly earnings that missed consensus estimates for both revenue and EPS.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The analyst rating change, combined with the disclosure of insider selling, affects investor sentiment regarding Ironwood Pharmaceuticals. The company’s recent quarterly results showed a negative return on equity of 58.38% and a net margin of 33.36%.

From themarketsdaily.com

Who's involved

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • The company might see changes in stock demand or funding based on the analyst rating and insider selling disclosures.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped